

**Dr. Moshik Cohen Kutner** is Co-Founder and Chief Executive Officer of **Omnix Medical Ltd.**, a clinical-stage biotechnology company developing novel anti-infective therapies to address the growing global threat of antimicrobial resistance (AMR). Since co-founding the company in 2015, Dr. Cohen Kutner has led Omnix's strategic direction, corporate development, and financing efforts, advancing its proprietary platform and lead program, OMN6, from early scientific exploration through clinical development.

Driven by the urgent need for innovative solutions against multidrug-resistant Gram-negative pathogens, he has played a central role in shaping OMN6's scientific and clinical development strategy and expanding the company's intellectual property portfolio. Under his leadership, Omnix has generated compelling in vivo and clinical data supporting its differentiated mechanism of action and therapeutic potential.

Dr. Cohen Kutner has raised over **\$50M** in private and public financing to support Omnix's research, development, and operational growth. Omnix's programs have also received support from highly prestigious and competitive funding frameworks, including the European Union's Horizon programs, the U.S. National Institutes of Health (NIH), and the Israel Innovation Authority—further validating the scientific strength and global relevance of the company's technology.

Combining scientific expertise with entrepreneurial leadership, Dr. Cohen Kutner is committed to translating innovative science into impactful therapies aimed at combating life-threatening resistant infections worldwide.